Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "L01XG" (18)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
Bortezomib (L01XG01) 12 products
WHO-DDD
L
IP
Velcade 1 mg
Durchstechflasche(n)
148.27
176.30
10 %
Lyophilisate: Bortezomibum 1 mg
Janssen-Cilag AG
A / SL / SO
FB
G
L
IP
Velcade 3.5 mg
Durchstechflasche(n)
410.05
460.10
10 %
Lyophilisate: Bortezomibum 3.5 mg
Janssen-Cilag AG
A / SL / SO
FB
G
L
IP
Bortezomib Accord liquid 2.5
mg/1 ml
270.98
311.10
10 %
Injection solution: Bortezomibum 2.5 mg/ml
Accord Healthcare AG
A / SL / SG
FB
G
L
IP
Bortezomib Accord liquid 3.5
mg/1.4 ml
372.78
421.85
10 %
Injection solution: Bortezomibum 3.5mg / 1.4ml
Accord Healthcare AG
●
A / SL / SG
FB
G
L
IP
Bortezomib liquid Spirig HC 3.5
mg/1.4 ml
372.78
421.85
10 %
Injection solution: Bortezomibum 3.5mg / 1.4ml
Spirig HealthCare AG
A / SL / SG
FB
G
L
IP
Bortezomib liquid Spirig HC 7
mg/2.8 ml
641.18
713.75
10 %
Injection solution: Bortezomibum 7mg / 2.8ml
Spirig HealthCare AG
●
A / SL / SG
FB
G
L
IP
Bortezomib Zentiva 1.0 mg
126.04
153.50
10 %
Lyophilisate: Bortezomibum 1 mg
Helvepharm AG
A / SL / SG
FB
G
L
IP
Bortezomib Zentiva 3.5 mg
372.78
421.85
10 %
Lyophilisate: Bortezomibum 3.5 mg
Helvepharm AG
A / SL / SG
FB
G
L
IP
Bortezomib Sandoz 1 mg
126.04
153.50
10 %
Dry substance: Bortezomibum 1 mg
Sandoz
Pharmaceuticals AG
A / SL / SG
FB
G
L
IP
Bortezomib Sandoz 3.5 mg
372.78
421.85
10 %
Dry substance: Bortezomibum 3.5 mg
Sandoz
Pharmaceuticals AG
A / SL / SG
FB
G
L
IP
Bortezomib Accord 1 mg
126.04
153.50
10 %
Pulver zur Herstellung einer lnjektionslösung: Bortezomibum 1 mg
Accord Healthcare AG
A / SL / SG
FB
G
L
IP
Bortezomib Accord 3.5 mg
372.78
421.85
10 %
Pulver zur Herstellung einer lnjektionslösung: Bortezomibum 3.5 mg
Accord Healthcare AG
A / SL / SG
FB
G
Carfilzomib (L01XG02) 3 products
WHO-DDD
L
IP
PP
Kyprolis 10 mg
170.85
202.25
10 %
Lyophilisate: Carfilzomibum 10 mg
Amgen Switzerland AG
A / SL
FB
G
L
IP
PP
Kyprolis 30 mg
512.54
573.85
10 %
Lyophilisate: Carfilzomibum 30 mg
Amgen Switzerland AG
A / SL
FB
G
L
IP
PP
Kyprolis 60 mg
Durchstechflasche(n)
1025.08
1131.25
10 %
Lyophilisate: Carfilzomibum 60 mg
Amgen Switzerland AG
A / SL
FB
G
Ixazomib (L01XG03) 3 products
WHO-DDD
L
IP
CI
PP
Ninlaro 2.3 mg
3
4836.08
5269.60
10 %
Capsules: Ixazomibum 2.3 mg
Takeda Pharma AG
A / SL
FB
G
L
IP
CI
PP
Ninlaro 3.0 mg
3
4836.08
5269.60
10 %
Capsules: Ixazomibum 3 mg
Takeda Pharma AG
A / SL
FB
G
L
IP
CI
PP
Ninlaro 4.0 mg
3
4836.08
5269.60
10 %
Capsules: Ixazomibum 4 mg
Takeda Pharma AG
A / SL
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2026
©ywesee GmbH
Settings
|
Help
|
Login
|
Contact
|
Home
